Meet our CEO, Ivo Timmermans, and Dan Gelvan, our Chief R&D Officer, at ASCO22 to discuss Pleco’s unconventional approach to treat cancer. Our current focus is on rare diseases such as AML and SCLC, both cancers are highly resistant to #treatment.

To book a meeting, please email info@plecotherapeutics.com